ClinicalTrials.gg
Not yet recruitingNCT06736912Updated Dec 17, 2024

This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

A Phase 1 interventional study of IN-114199 2.5mg or placebo and IN-114199 10mg or placebo in Chronic Idiopathic Constipation, sponsored by HK inno.N Corporation. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 63 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Constipation with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Constipation · Korea, Republic of.

Planned enrollment
9th of 20
80 · median 80
Started
2024
the only one that year
Phase 1
2 of 23
1 open now
Registered
21st of 23
by date
Lead sponsor
1 of 23
HK inno.N Corporation

Among the 23 studies in Constipation with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 1, and was the 21st registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

2 of the 23 studies in Constipation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 19 Years to 63 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Constipation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and food effect of IN-114199 in healthy participants

Read the detailed description

Part A: SAD and FES study

  • To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of a single oral dose of IN-114199 in healthy adults
  • To compare and evaluate the effects of food on the safety, tolerability, pharmacokinetic and pharmacodynamic properties of a single oral dose of IN-114199 in healthy adults

Part B: MAD study

  • To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of repeated oral doses of IN-114199 in healthy adults
03

Conditions studied

  • Chronic Idiopathic Constipation

Browse trials for

04

Who can participate

Ages eligible
19 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged ≥ 19 years and ≤ 63 years on the date of the written
  • Healthy subjects were defined as individuals who defecated almost every day for ≥ 6 months
  • Body weight of ≥ 40.0 kg and ≤ 100.0 kg, with (BMI) of ≥ 18.5 kg/m2 and ≤ 29.9 kg/m2 at the time of screening
  • Those who have fully understood this clinical trial via detailed explanation, were willing to voluntarily participate in this study, and agreed to give written informed consent prior to the screening procedure.
  • Those who are judged eligible for this study upon judgment of the investigator in screening tests established depending on the characteristics of product (examinations by interview, clinical laboratory test, physical examinations, etc.).

Exclusion criteria

Exclusion Criteria:

  • Presence or history of liver, kidney, nervous system, respiratory system, endocrine system, blood and tumor, cardiovascular system, urinary system or psychiatric disease
  • Presence or history of gastrointestinal disorder (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) that may influence the safety and pharmacodynamic assessments of the product and history of gastrointestinal surgery (except simple appendectomy and hernia surgery), hemostatic disorder or hemorrhage-related disease
  • to drugs including the ingredients of the investigational product and other drugs (aspirin, antibiotics, etc.) or history of clinically significant hypersensitivity
  • Positive result in serology tests ( test, test, (HIV) test, syphilis test)
  • Subjects who have history of drug abuse, or who have a positive urine test for drugs of abuse.
  • Blood (SGOT), and ALT(SGPT) > 60 IU/L at the screening test
  • Showing the following findings on at the screening test: > 480 msec(all), QTcB>450(male), QTcB>470(female)
  • Subjects who have taken any drugs known to significantly induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 1 month prior to the expected initial application date.
  • Subjects who have participated in other clinical trials within 6 months prior to the expected initial application date
  • Subjects who have history of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g = 12.5 mL of pure alcohol) or subjects who cannot avoid drinking alcohol from 3 days prior to the expected initial application date to the discharge
  • Subjects who have history of average use of 10 cigarettes daily
  • Subjects who consumed caffeine-containing food (coffee, green tea, black tea, carbonated beverage, coffee-flavored milk, tonics, etc.) or subjects who cannot avoid drinking caffeine-containing food from 3 days prior to the expected initial application date to the discharge
  • Subjects are unable to use a highly effective method of (e.g., correctly placed intrauterine device(IUD), sterilization surgery (vasectomy, tubal ligation, etc.))
  • Subjects who are judged ineligible for the clinical study by the investigator due to reasons other than the above inclusion/exclusion criteria.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Part I(Cohort I) IN-114199 2.5 mg or Placebo

    SAD

    Drug: IN-114199 2.5mg or placebo

  • Experimental
    Part I(Cohort 2) IN-114199 5 mg or Placebo

    SAD and FES

    Drug: IN-114199 5mg or placebo

  • Experimental
    Part I(Cohort 3) IN-114199 10 mg or Placebo

    SAD and FES

    Drug: IN-114199 10mg or placebo

  • Experimental
    Part I(Cohort 4) IN-114199 20 mg or Placebo

    SAD and FES

    Drug: IN-114199 20mg or placebo

  • Experimental
    Part I(Cohort 5) IN-114199 40 mg or Placebo

    SAD

    Drug: IN-114199 40mg or placebo

  • Experimental
    Part II(Cohort I) IN-114199 2.5 mg or Placebo

    MAD

    Drug: IN-114199 2.5mg or placebo

  • Experimental
    Part II(Cohort 2) IN-114199 5 mg or Placebo

    MAD

    Drug: IN-114199 5mg or placebo

  • Experimental
    Part II(Cohort 3) IN-114199 10 mg or Placebo

    MAD

    Drug: IN-114199 10mg or placebo

  • Experimental
    Part II(Cohort 4) IN-114199 20 mg or Placebo

    MAD

    Drug: IN-114199 20mg or placebo

Interventions

  • DrugIN-114199 2.5mg or placebo

    IN-114199 2.5mg or placebo (1 Tablet, QD)

  • DrugIN-114199 10mg or placebo

    IN-114199 10mg or placebo (1 Tablet, QD)

  • DrugIN-114199 20mg or placebo

    IN-114199 10mg or placebo (2 Tablets, QD)

  • DrugIN-114199 40mg or placebo

    IN-114199 10mg or placebo (4 Tablets, QD)

  • DrugIN-114199 5mg or placebo

    IN-114199 2.5mg or placebo (2 Tablets, QD)

06

What researchers measure

Primary outcomes

  1. Adverse Event

    For all adverse events collected during the study, the investigator will evaluate serious adverse events, severity, or drug relationship

    Time frame: Up to Post Study Visit (Part I SAD: Day 7~Day 9/ Part I SAD, FES: Day 14~ Day 16/ Part II:Day 13~Day 15)

  2. Vital Sign

    Vital sign results will be classified as normal, not clinically significant, or clinically significant upon judgment of the investigator after single/multiple dosing of IN-114199

    Time frame: Part I : Up to Day 3/ Part II: Up to Day 9

  3. Physical Examination

    Physical examination results will be classified as normal, not clinically significant, or clinically significant upon a judgment of the investigator after single/multiple dosing of IN-114199.

    Time frame: Part I : Up to Day 3/ Part II: Up to Day 9

  4. Body Weight in kilograms Measurement

    The body weight in kilograms of Subjects will be monitored daily from the administration of IN-114199 until their discharge

    Time frame: Part I : Up to Day 3 / Part II: Up to Day 9

  5. 12-lead electrocardiogram (ECG)

    QT/QTc interval will be recorded and analyzed automatically.

    Time frame: Part I SAD: Up to Day 3 / Part II: Up to Day 9

  6. Clinical Laboratory Test

    Clinical laboratory test, the results will be classified as normal, not clinically significant, or clinically significant upon judgment of the investigator after single/multiple dosing of IN-114199

    Time frame: Part I:Day 1, Day 3/ Part II: Day 1, Day 3, Day 5, Day 7, Day 9

Secondary outcomes

  1. PK parameters (Urine and Plasma)

    Cmax

    Time frame: Part I SAD: Up to Day 3/ Part I SAD, FES: Up to Day 3 / Part II: Up to Day 9

  2. PK parameters (Urine and Plasma)

    AUClast

    Time frame: Part I SAD: Up to Day 3/ Part I SAD, FES: Up to Day 3 / Part II: Up to Day 9

  3. PD parameters (plasma C4 level)

    AUEClast

    Time frame: Part I SAD: Up to Day 3/ Part I SAD, FES: Up to Day 3 / Part II: Up to Day 9

  4. PD parameters (plasma LDL/HDL level)

    AUEClast

    Time frame: Part I SAD: Up to Day 2/ Part I SAD, FES: Up to Day 2 / Part II: Up to Day 8

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Aug 2025, 8 months later.

Of 13 phase 1 interventional studies under Constipation, half reached primary completion within 21 months of starting (the median); a quarter within 10 and three quarters within 38. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Dec 17, 2024
StartEst.
Dec 16, 2024
Primary completionEst.
Aug 30, 2025
CompletionEst.
Nov 11, 2025
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06736912
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Dec 16, 2024 (estimated)
Primary completion
Aug 30, 2025 (estimated)
Completion
Nov 11, 2025 (estimated)
Last update
Dec 17, 2024

Study contacts

Seung Hee Jung, Ph.D
Contact
shee.jung@inno-n.com
+82-2-6477-0164
Eun Ji Kim
Contact
eunji.kim24@inno-n.com
+82-2-6477-0290

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion